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The past decade has seen intensive efforts to define molecular
genetic events in breast cancer and to correlate these events with
its clinical behaviour. One of the most extensively studied genes is
the tumour suppressor gene p53, which encodes a nuclear phos-
phoprotein with cancer-inhibiting properties. The currently
accepted model for the function of the wild-type p53 protein is as
a multi-functional transcription factor involved in the control of
cell cycle progression, DNA integrity and cell survival in cells
exposed to DNA-damaging agents (Lane, 1992). Arrest of cell
cycle progression following DNA damage is thought to represent a
basic protective mechanism preventing replication of damaged
template DNA. Most of the biologically significant mutations
impair the ability of p53 to participate in the maintenance of
genomic stability. As a result, tumours lacking normal p53 might
be prone to other deleterious mutations and to be more aggressive
clinically.
Many studies have investigated the association between breast
cancer prognosis and p53 protein expression in tumour cells with
conflicting results. Although most studies have shown a poorer
prognosis for breast cancers with increased p53 expression (Thor
et al, 1992; Allred et al, 1993; Barnes et al, 1993; Silvestrini et al,
1993; Elledge et al, 1994; Stenmark-Askmalm et al, 1994; Beck et
al, 1995; Levesque et al, 1998), others have found no difference
(Isola et al, 1992; Bianchi et al, 1997) or even improved (Lipponen
et al, 1993; Gohring et al, 1995) survival in this group of cancers.
The use of immunohistochemistry (IHC) is based on the fact that
mis-sense mutations usually result in an increased half-life of the
protein product and a consequent accumulation of the mutant p53
protein in the nucleus. However, many antibodies used are unable
to discriminate between the wild-type and mutant p53. Moreover,
approximately 20% of p53 mutations result in protein truncation
and these will not be identified by IHC, which has been shown to
have a sensitivity of 72% and specificity of 92% compared with
sequencing of cDNA to detect p53 mutations (Norberg et al,
1998).
For these reasons, studies of the association between p53 muta-
tions and outcome in breast cancer should provide a more reliable
indication of the prognostic value of alterations in p53. As
expected, most investigators have reported poorer overall and
disease-free survival (as indicated by a relative hazard (RH)
greater than one) in breast cancer cases with somatic mutations in
p53. In a recent review, Hartmann et al (1997) concluded that
‘mutations in the p53 gene predict poor outcome in breast cancer’.
However, different studies have produced widely differing RH
estimates, ranging from no risk (RH = 1) to a relative hazard of 23
and not all of these results have been statistically significant.
The aim of this report was to identify all the published studies
which have investigated the association between somatic muta-
tions in the p53 gene and breast cancer prognosis, and to use stan-
dard techniques of meta-analysis to combine the results of these
studies to produce a more precise estimate of the prognostic signif-
icance of p53 mutations.
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Summary Many studies have investigated the association between alterations in the p53 gene and clinical outcome of breast cancer, and
most investigators have reported poorer overall and disease-free survival (as indicated by a relative hazard (RH) greater than one) in breast
cancer cases with somatic mutations in p53. However, different studies have produced widely differing RH estimates, ranging from no risk
(RH = 1) to a relative hazard of 23, and not all of these results have been statistically significant. We have therefore reviewed all the published
studies that have investigated the association between somatic mutations in the p53 gene and breast cancer prognosis and used standard
techniques of meta-analysis to combine the results of these studies to produce a more precise estimate of the prognostic significance of p53
mutations. Eleven studies investigated overall survival in a total of 2319 unselected cases. The RH estimates from these ranged from 1 to
23.4 with a combined RH estimate of 2.0 (confidence interval 1.7–2.5). Three studies investigated the role of p53 in node-negative patients
and in these, the combined estimate of RH was 1.7 (1.2–2.3). For three studies of node-positive breast cancer the combined risk estimate
was 2.6 (1.7–3.9). The inclusion of p53 mutation screening in large breast cancer clinical trials seems warranted in the light of these results.
Analysis of large numbers of cases matched for stage and therapy will allow definitive clarification of the value of p53 mutational status in
prognostication, and possibly choice of therapy.
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METHODS
Studies investigating the role of somatic mutations in p53 and
prognosis in breast cancer were identified using the Medline
(National Library of Medicine, Washington, DC, USA) and BIDS
databases for 1983 to July 1998 using the search terms ‘breast-
neoplasms’ and ‘p53’ and ‘mutation’. The bibliographies of any
studies identified were also hand searched. Eligible studies were
those that reported a survival analysis in breast cancer cases that
had been tested for the presence of somatic mutations in p53.
Where a single study had been reported on multiple occasions,
only the most recent report or the report with the most complete
data was included in the analysis. Studies that only investigated
p53 expression were excluded from the analysis.
Design of meta-analyses
Details of the calculations described below are given in the
Appendix. Combined estimates of risk were obtained by calcu-
lating a weighted average of the log relative hazard estimates.
Most studies report RH estimates adjusted for other prognostic
factors in a multivariate analysis. For the meta-analyses, the
adjusted values have been used. The 95% confidence intervals
(CI) described are either those published, or have been estimated
from published P-value associated with the RH estimate. Two
studies reported that there was no significant association between
p53 mutations and survival, without giving a RH estimate (Caleffi
et al, 1994; Gretarsdottir et al, 1996). In both these studies the
published survival curves for the two groups (p53 mutation + and
–) were very close, and so a RH of 1 was assigned. For the purpose
of the meta-analysis the weight assigned to the log (RH) for these
two studies was similar to the weight for other studies of the same
size.
RESULTS
Sixteen eligible studies were identified. Of these, the breast cancer
cases were unselected in 12, one was a small study of inflamma-
tory breast carcinoma (Riou et al, 1993), and three included only
cases of node-negative breast cancer. The study of node-negative
cancer by Iacopetta et al (1998) was a more detailed analysis of a
subset of patients included in a larger study first reported by
Seshadri et al (1996).
Table 1 shows the results of p53 mutation testing in the different
studies. A variety of techniques were used to identify genetic alter-
ations including single-strand conformation polymorphism
(SSCP), constant denaturing gel electrophoresis (CDGE), dideoxy
fingerprinting (ddF) and DNA sequencing. The number of alter-
ations identified by each study are shown in Table 1. Alterations
were identified in 539 of 2993 cases tested (18%). This is likely to
be an underestimate because most studies limited the analysis to
exons 5–8. Around 10% of alterations were found to occur outside
this region in studies that analysed other exons (see Table 1). For
most of the studies where sequencing was not the primary method
for identifying mutations, confirmation of some or all of the alter-
ations identified was carried out by sequencing: 319 (59%) of 539
alterations were confirmed by sequencing, of which 232 (73%)
were mis-sense mutations, 20 (6%) were non-sense mutations, 40
(13%) were insertions or deletions resulting in a frameshift, and 26
(8%) were other changes including splice site mutations, complex
variants, and in-frame deletions/insertions (Table 1).
Table 1 Results of p53 mutation testing for individual studies
Study Mutation detection Case selection No. of p53 Sequencing results
methoda cases alternations
n (%) Total MS NS F IF Other
Andersen et al, 1993 CDGE exons 5–8 Unselected 163 35(22) 35 27 (77) 2 (6) 6 (17) 0 0
Bergh et al, 1995 Sequencing cDNA Unselected consecutive series 312 69 (22) 69 45 (65) 7 (10) 11 (16) 6 (9) 0
Node-positive 97 29 (30) NA
Node-negative 201 36 (18) NA
Berns et al, 1998 SSCP exons 5–8 Unselected 222 77 (35) 66 54 (78) 1 (2) 4 (6) 0 7 (11)
Caleffi et al, 1994 CDGE exons 5–9 Unselected 192 43 (22) 21 18 (86) 2 (10) 0 0 1 (5)
Elledge et al, 1993 SSCP exons 5–9 Node-negative 200 28 (14) 4 1 (25) 0 2 (50) 0 1 (25)
Falette et al, 1998 Sequencing exons 2–11 Node-negative 113 18 (16) 18 18 (100) 0 0 0 0
Gretarsdottir, 1996 CDGE exons 5–8 Unselected 186 30 (16) 17 12 (71) 1 (6) 2 (12) 0 1 (6)
Iacopetta et al, 1998 SSCP exons 4–8 Node-negative 422 75 (18) NA
Kovach et al, 1996 ddF exons 4–10 Unselected consecutive series 44 13 (30) 13 8 (62) 0 2 (15) 3 (23) 1 (8)
Riou et al, 1993 Sequencing Inflammatory breast cancer 24 9 (38) 5 (56) 1 (11) 1 (11) 1 (11) 0 1 (11)
Saitoh et al, 1994 ddF exons 2–11 Unselected 52 21 (39) 9 (44)
Seshadri et al, 1996 SSCP exons 5–6 Unselected 727 57 (8) NA
Node-negative 424 NA NA
Node-positive 303 NA NA
Shiao et al, 1995 SSCP exons 5–8 Unselected 92 18 (20) 18 10 (56) 2 (11) 2 (11) 0 4 (22)
White American 47 9 (19) 9 7 (78) 0 1 (11) 0 1 (11)
Black American 45 9 (20) 9 3 (33) 2 (22) 1 (11) 0 3 (33)
Soong et al, 1997 SSCP exons 4–10 Unselected 375 70 (19) 21 14 (67) 2 (10) 5 (23) 0 0
Thorlacius et al, 1995 CDGE exons 5, 7, 8 Unselected 106 20 (19) 20 14 (70) 1 (5) 5 (25) 0 0
Tsuda, 1998 SSCP exons 4–8 Node-positive 150 38 (25) NA
Valgardsdottir, 1997 CDGE exons 5–8 Unselected 87 14 (17) 12 10 (83) 1 (8) 0 1 (8) 0
MS, mis-sense; NS, non-sense; F, frameshift; IF, in-frame insertion/deletion; SSCP, single-strand conformation polymorphism; CDGE, constant denaturing gel
electrophoresis; ddF, dideoxy fingerprinting.1970 PDP Pharoah et al
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The results of survival analyses are given in Table 2. The
numbers of cases included in these analyses was frequently less
than the number tested for mutations, because of incompleteness
of data. Median follow-up ranged from 24 to 120 months. Eleven
studies investigated overall survival in a total of 2319 unselected
cases (Andersen et al, 1993; Caleffi et al, 1994; Bergh et al, 1995;
Shiao et al, 1995; Thorlacius et al, 1995; Gretarsdottir et al, 1996;
Kovach et al, 1996; Seshadri et al, 1996; Soong et al, 1997;
Valgardsdottir et al, 1997; Berns et al, 1998). The RH estimates
from these ranged from 1 to 23.4 with a combined RH estimate of
2.0 (CI 1.7–2.5). However, this result needs to be interpreted with
some caution as there was evidence for heterogeneity amongst the
studies (c2 = 23.2, 10 d.f., P = 0.01). Outcome for node-negative
breast cancer according to p53 mutation status was reported in
three studies totalling 736 patients (Bergh et al, 1995; Falette et al,
1998; Iacopetta et al, 1998), one of which was a sub-group
analysis of an unselected case series (Bergh et al, 1995). The
combined estimate of RH for these was 1.7 (1.2–2.3). Three
studies of node-positive breast cancer (Bergh et al, 1995; Seshadri
et al, 1996; Tsuda et al, 1998), two of which were sub-group
analyses, were carried out for 550 node-positive cases with a
combined risk estimate of 2.6 (1.7–3.9). Although the overall
survival RH was higher in the node-positive than the node-nega-
tive cases there was no statistically significant difference between
them (c2 = 2.79, 1 d.f., P = 0.09). Disease-free survival was inves-
tigated in five studies of 790 unselected patients (Andersen et al,
1993; Gretarsdottir et al, 1996; Kovach et al, 1996; Seshadri et al,
1996; Berns et al, 1998). The combined relative hazard was 1.5
(1.1–1.9). Two studies of 612 node-negative cases (Elledge et al,
1993; Iacopetta et al, 1998) had a combined RH of 1.7 (1.2–2.4)
for disease-free survival.
Several studies have compared the predictive value of p53
mutations with that of p53 protein expression (Thorlacius et al,
1995; Kovach et al, 1996; Valgardsdottir et al, 1997; Falette et al,
1998; Iacopetta et al, 1998; Norberg et al, 1998). As would be
expected, given the shortcomings of immunohistochemical tech-
niques for the detection of abnormal p53 protein products, all but
one of these (Tsuda et al, 1998) found that p53 mutations were of
greater prognostic value than p53 expression.
Table 2 Results of survival analyses for individual studies
Study No. of cases Relative hazard (95% CI) Variables included in Comments
(median follow-up multivariate analysis
in months) Relapse Death
Andersen et al, 1993 Unselected 163 (48) 2.3 (1.2–4.4) 2.9 (1.2–7.1) N,T
Bergh et al, 1995 Unselected consecutive series 312 (57) NA 2.0 (1.0–3.9) A, N, T, ER, S, TX
Node-positive 97 NA 2.4 (1.1–5.4) A, N, T, ER, S, TX
Node-negative 201 NA 1.1 (NA) A, N, T, ER, S, TX
Berns et al, 1998 Unselected 177 (115) 1.6 (1.1–2.4) 1.5 (0.97–2.2) A, N, T, ER, M, c-myc
Caleffi et al, 1994 Unselected 192 (48) NA not significant Univariate model
Elledge et al, 1993 Node-negative 155 (71) 2.2 (1.1–4.3) NA A, T, ER, PR, S
Falette et al, 1998 Node-negative 113 (105) NA 1.81 (0.99–3.30) A, T, ER, PR, G
Gretarsdottir, 1996 Unselected 186 (120) 1.0 (0.9–1.4) 1.0 (0.9–1.4) Univariate model 70% of cases in Iceland 1981–1983
Iacopetta et al, 1998 Node-negative 422 (74) 1.6 (1.1–2.5) 2.1 (1.3–3.5) T, ER, HER-2/neu, MIB-1 Included data from study first reported
by Seshadri et al, 1996
Kovach et al, 1996 Unselected consecutive series 90 (24) 4.7 (1.4–16) 23.4 (2.4–228) N, T, ER, PR Included data from study first reported
by Saitoh et al, 1994
Riou et al, 1993 Inflammatory breast cancer 24 (54) NA 8.6(1.4–52.5) Inflammatory symptoms,
ER, p53 expression
Seshadri et al, 1996 Unselected 727 (NA) 2.3 (1.5–3.5) 2.4 (1.5–3.8) N, T, ER, HER-2/neu
Node-negative 424 1.9 (1.0–3.4) 2.0 (1.0–4.0) T, ER
Node-positive 303 2.5 (1.4–4.4) 2.7 (1.5–5.0) T, ER
Shiao et al, 1995 Unselected 92 (NA) NA NA
Whites 47 NA 5.6 (1.4–23.0) A, S
Blacks 45 NA 0.81 (0.07–5.51) A, S
Soong et al, 1997 Unselected 198 (57) NA 2.5 (1.2–5.2) N, S, ER
Thorlacius et al, 1995 Unselected 106 (32) NA 3.3 (1.6–6.7) A, N, T
Tsuda, 1998 Node-positive 150 (44) 1.9 (1.1–3.3) 2.7 (1.2–5.9) Univariate
Valgardsdottir, 1997 Unselected 81 (42) NA 6.6 (2.1–20.3) A, T, N
A, age; N, nodal status; T, tumour size; ER, oestrogen receptor status; G, histological grade; PR, progesterone receptor status; M, menopausal status;
S, S phase index; c-myc, c-myc amplification; TX, type of therapy.
Table 3 p53 mutations and survival – results of the meta-analyses
Total no. of cases Relative hazard (95%CI) Homogeneity test
c2 (d.f.) P-value
Overall survival
Unselected 2319 2.0 (1.7–2.5) 23.2 (10) 0.01
Node-negative 736 1.7 (1.2–2.3) 2.63 (2) 0.27
Node-positive 550 2.6 (1.7–3.9) 0.06 (2) 0.97
Disease-free survival
Unselected 790 1.5 (1.2–1.9) 9.2 (4) 0.06
Node-negative 612 1.7 (1.2–2.4) 0.21 (1) 0.65Somatic p53 mutations and prognosis in breast cancer 1971
British Journal of Cancer (1999) 80(12), 1968–1973 © 1999 Cancer Research Campaign
DISCUSSION
We have identified 16 studies that have investigated the associa-
tion between somatic mutations in the p53 gene and survival in
breast cancer. The proportion of breast cancers with mutations in
p53 reported in these studies is similar to that from other studies
(Hartmann et al, 1997), and the spectrum of mutations is similar to
that reported on the p53 mutations database (International Agency
for Research into Cancer, 1998). Greater than 90% mutations
reported to this database occur in exons 5–8, and of these, 72% are
mis-sense mutations, 7% non-sense, 15% frameshift and 6% other.
Most, but not all, studies found that survival was significantly
poorer in cancers with a p53 mutation. In the meta-analysis, the
association between p53 mutation and overall survival was
confirmed for unselected, node-negative and node-positive breast
cancer. It is possible that this association is the result of
confounding by some other factor. However, most studies carried
out multivariate analyses to control for a variety of other known
prognostic markers, and whichever factors were included in these
analyses, p53 was retained in the final multivariate models. In
addition, where the results of both univariate and multivariate
analyses were reported, the univariate RHs for p53 mutations were
little different from the multivariate RHs. This suggests that p53 is
an independent prognostic marker.
The possibility of bias also exists, and in interpreting the results
of a meta-analysis, three important questions need to be asked:
1. Have all relevant published studies been identified?
2. Are the results of the studies compatible with each other
(is there heterogeneity)?
3. Has there been publication bias?
Whether we have been able to ascertain completely all relevant
studies is unclear. However, we believe we have identified all
published studies in which a survival comparison between breast
cancers with and without p53 mutations was a major component of
the study. The importance of possible study heterogeneity is also
difficult to assess. Given the differences between studies in study
populations, treatment regimens, methods for determining p53
mutation status, and measurement of potential confounding
factors, some degree of heterogeneity between studies is expected.
Indeed, for the 11 studies with unselected cases, there was statis-
tical evidence of heterogeneity, with no single study making a
substantial individual contribution to the heterogeneity statistic.
Whether it is then appropriate to combine the results of these
studies depends to some extent on the sources of that hetero-
geneity. For example, there is some evidence that the prognostic
significance of p53 mutations varies between node-negative and
node-positive patients, and so differences in patient populations
with respect to node status could account for some of the hetero-
geneity. However, the effect of this is likely to be limited as, where
reported, the proportion of node-negative patients was similar in
the various studies. Publication bias (discussed below) is another
potential source of heterogeneity, and likely to be more important.
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Figure 1 Funnel plot of relative hazard of overall survival for breast cancer
cases with somatic mutation in p53 by individual study. Studies are plotted in
order according to the variance of the log relative hazard estimate. Tendency
for smaller studies to have effect sizes greater than the common risk
estimate provides evidence for publication bias (see text)
Figure 2 Funnel plot of relative hazard of disease-free survival for breast
cancer cases with somatic mutation in p53 by individual study1972 PDP Pharoah et al
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The possibility of publication bias – that is the non-publication
of studies with findings that are not statistically significant – is a
major concern in any systematic review. If publication bias is oper-
ating, one would expect that of published studies, the larger ones
report the smaller effects. This is because small positive trials are
more likely to be published than small negative ones (Egger and
Smith, 1995). The occurrence of this can be examined using the
funnel plot (Figure 1) in which the effect size is plotted against
sample size/variance. In the absence of publication bias, the plot
will resemble an inverted funnel centred on the combined risk esti-
mate, with the results of the smaller studies being more widely
scattered than those of the larger studies. This, however, does not
occur for the 11 studies of unselected cases. The seven larger
studies are fairly evenly scattered about the common risk estimate,
but for the four smaller studies, the RH estimate increases
inversely with study. This suggests, as predicted, that there has
been selective publication of small studies with significant positive
results. Because these studies are small, they carry less weight than
the larger studies, and have only a minor effect on the combined
RH estimate. Excluding the four smallest studies from the
combined analysis reduces the combined RH estimate from 2.0
(1.7–2.5) to 1.8 (1.4–2.3). Although the observed publication bias
will produce an overestimate of the true association, it is extremely
unlikely that publication bias has resulted in a Type I error; that is
the finding of a significant association, where no such association
exists. We estimate that a study or studies of 1500 cases with RH
of 0.5 (i.e. in the opposite direction to that expected) would be
needed to change the statistically significant RH for overall
survival to statistical non-significance.
We have confirmed that, in general, mutations in p53 confer a
worse overall survival and disease-free survival in breast cancer
cases, and this effect is independent of other risk factors. Whether
the prognostic significance of all mutations is the same is open to
doubt. Bergh et al (1995) reported that prognosis for mutations in
conserved regions II and V was worse than for mutations in the
conserved regions III and IV and non-conserved regions, and
Borresen et al (1995) reported that mutations in the zinc-binding
domain (Codon 163–195 and 236–251) have worse prognosis than
mutations elsewhere.
Doubt also remains about the therapeutic significance of p53
mutations. One study suggested that locoregional radiotherapy
improves survival in breast cancer cases with p53 mutations but
not for those with wild-type p53 (Jansson et al, 1995). However,
another study found that adjuvant systemic therapy, especially
with tamoxifen, along with radiotherapy seemed to be of less value
to p53 mutation tumours (Bergh et al, 1995), and Aas et al (1996)
found that p53 mutations were associated with primary resistance
to doxorubicin therapy. If these findings were to be confirmed,
they would have significant clinical implications.
Answers to questions of the prognostic and therapeutic signifi-
cance of p53 status are most likely to be obtained by the inclusion
of p53 mutation screening in large breast cancer clinical trials.
Although costly, the cost would be justified by the clinical impor-
tance of the questions. Only an analysis of large numbers of cases
matched for tumour size and nodal status and therapy will allow
definitive clarification of the added value of p53 mutational status
in prognostication, and possibly choice of therapy.
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APPENDIX
Estimation of 95% confidence intervals (CIs) for relative
hazard (RH) where not reported in individual study
bi = In (RH) for individual study
SE(bi) = bi/za/2 where a = p-value
UCI(bi),LCI(bi) = bi ± 1.96 ´ SE(bi)
Exponentiation of UCI(bi),LCI(bi) gives UCI(RH), LCI(RH).
Estimation of common RH
The combined estimate of the log RH was estimated from the
weighted average of the logarithms of the observed (individual
study) RHs (Breslow and Day, 1980).
Let b = log(common RH)
Where wi = weight individual studies = 1/variance
SE(b) = 1/ÖS wi
The common RH with 95% confidence intervals is then
obtained by exponentiation.
Testing for homogeneity of individual RH estimates
The null hypothesis of homogeneity of individual RH estimates
was tested by the c2 statistic on I21 degrees of freedom, where I
equals number of studies, using the formula
S wibi
Then b =  with confidence intervals UCI(b),LCI(b) = b±1.96 ´ SE(b)
S wt
log(UCI)–log(LCI)
variance =
3.922
[S wibi]2
c2
I21 = S wib2
i – 
S wi